Condition: Adenovirus Infections · Cytomegalovirus Infection · Sponsor: SymBio Pharmaceuticals
The purpose of this study is to determine the safety and tolerability of intravenous (IV) brincidofovir (BCV; SyB V-1901) 0.2 mg/kg, 0.3 mg/kg or 0.4 mg/kg dosed twice weekly (BIW) or 0.4 mg/kg dosed once weekly (QW) for 4 weeks in subjects with AdV, and IV BCV in subjects with CMV
This description comes directly from the study's public registry record.
Kohji Shimasaki · +81-3-6684-6616 · MedInfo@symbiopharma.com
Rochelle Maher · +1-917-656-6951 · rmaher@symbiopharma.com
Always discuss trial participation with your own doctor first.
| Research Site | Los Angeles, California, United States | Recruiting |
| Research Site | Los Angeles, California, United States | Completed |
| Research Site | San Francisco, California, United States | Completed |
| Research Site | Chicago, Illinois, United States | Recruiting |
| University of Nebraska Medical Center | Omaha, Nebraska, United States | Recruiting |
| Research Site | Durham, North Carolina, United States | Recruiting |
| Cincinnati Children's Hospital Medical Center | Cincinnati, Ohio, United States | Recruiting |
| Research Site | Philadelphia, Pennsylvania, United States | Recruiting |
| St. Jude Children's Research Hospital | Memphis, Tennessee, United States | Recruiting |
| MD Anderson Cancer Center | Houston, Texas, United States | Recruiting |
| Research Site | Seattle, Washington, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04706923